{
    "clinical_study": {
        "@rank": "70569", 
        "arm_group": [
            {
                "arm_group_label": "Ibuprofen + Paracetamol", 
                "arm_group_type": "Active Comparator", 
                "description": "Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses\n+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses"
            }, 
            {
                "arm_group_label": "Ibuprofen + Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses\n+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if adding paracetamol to ibuprofen is superior to\n      ibuprofen only for treatment of patent ductus arteriosus (PDA) in preterm infants."
        }, 
        "brief_title": "Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants", 
        "condition_browse": {
            "mesh_term": "Ductus Arteriosus, Patent"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Preterm infants born at 24-37 gestational age\n\n          -  diagnosis of Hemodynamically significant patent ductus arteriosus\n\n          -  Medical staff decided to treat with Ibuprofen\n\n          -  Parents have signed informed consent\n\n        Exclusion Criteria:\n\n          -  Contraindication for ibuprofen\n\n          -  Alanine transaminase /Aspartate transaminase\u2265 200 U/L\n\n          -  Significant congenital heart disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "2 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002741", 
            "org_study_id": "IBUACA CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ibuprofen + Paracetamol", 
                "description": "Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h", 
                "intervention_name": "Paracetamol", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Acetaminophen", 
                    "Acamol"
                ]
            }, 
            {
                "arm_group_label": "Ibuprofen + Placebo", 
                "description": "Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "NaCl 0.9%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Ibuprofen"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "patent ductus arteriosus", 
            "PDA", 
            "Preterm", 
            "Infant", 
            "Electrocardiography", 
            "Paracetamol", 
            "Acamol", 
            "ibuprofen", 
            "Placebo"
        ], 
        "lastchanged_date": "December 1, 2013", 
        "location": {
            "contact": {
                "email": "o_hochwald@rambam.health.gov.il", 
                "last_name": "Ori Hochwald, MD", 
                "phone": "972-4-8542219"
            }, 
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel", 
                    "zip": "31096"
                }, 
                "name": "Rambam Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial", 
        "overall_contact": {
            "email": "o_hochwald@rambam.health.gov.il", 
            "last_name": "Ori Hochwald, MD", 
            "phone": "972-4-8542219"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "By echocardiography", 
                "measure": "The incidence of patent ductus arteriosus closure", 
                "safety_issue": "No", 
                "time_frame": "3-10 days after first dose of Ibuprofen + study drug"
            }, 
            {
                "measure": "The need for surgical ligation for PDA", 
                "safety_issue": "No", 
                "time_frame": "3-21 days after first dose of Ibuprofen + study drug"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002741"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Renal and liver function, gastrointestinal complications will be assessed from the patient's medical records", 
            "measure": "Adverse effects", 
            "safety_issue": "Yes", 
            "time_frame": "until discharge home (usually within 2-3 months since recruitment)"
        }, 
        "source": "Rambam Health Care Campus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rambam Health Care Campus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}